Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Decitabine Plus Ivosidenib in Older or Unfit Patients With Newly Diagnosed AML
NCT07507760Phase 2Recruiting
- Sponsor
- Fundación PETHEMA
- Start
- Jun 2026
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ivosidenib, inqovi in acute myeloid leukemia (AML), sponsored by Fundación PETHEMA. Started Jun 2026; status: recruiting.
02
Drugs
ivosidenibinqovi
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07507760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07507760.